Abstract：With the deepening of the research on the “gut-kidney axis”, the relationship between trimethylamine-N-oxide, the metabolic compound of intestinal flora, and chronic kidney disease has become a research hotspot for scholars at home and abroad, providing a new target for the prevention and treatment of chronic kidney disease. This paper reviews the relationship between trimethylamine-N-oxide and chronic kidney disease in recent years, and the promotion of cardiovascular disease, cognitive impairment, peritonitis, cerebrovascular disease, and other complications through inducing oxidative stress and inflammatory response, in order to provide reference ideas for the clinical prevention and treatment of chronic kidney disease and its related complications.
杨翔滟1 田茂露2 查艳1. 氧化三甲胺与慢性肾脏病及其并发症关系的研究进展[J]. 中国医药导报, 2023, 20(11): 57-60.
YANG Xiangyan1 TIAN Maolu2 ZHA Yan1. Research progress on the relationship between trimethylamine-N-oxide and chronic kidney disease and its complications. 中国医药导报, 2023, 20(11): 57-60.
[1] Yancey PH，Speers-Roesch B，Atchinson S，et al. Osmolyte Adjustments as a Pressure Adaptation in Deep-Sea Chondrichthyan Fishes：An Intraspecific Test in Arctic Skates （Amblyraja hyperborea） along a Depth Gradient [J]. Physiol Biochem Zool，2018，91（2）：788-796.
[2] Lim YJ，Sidor NA，Tonial NC，et al. Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease： Mechanisms and Therapeutic Targets [J]. Toxins （Basel），2021，13（2）：142.
[3] Gatarek P，Kaluzna-Czaplinska J. Trimethylamine N-oxide （TMAO） in human health [J]. Excli J，2021，20：301-319.
[4] El-Deeb OS，Atef MM，Hafez YM. The interplay between microbiota-dependent metabolite trimethylamine N-oxide，Transforming growth factor β/SMAD signaling and inflammasome activation in chronic kidney disease patients： A new mechanistic perspective [J]. J Cell Biochem，2019，120（9）：14476-14485.
[5] Zou D，Li Y，Sun G. Attenuation of Circulating Trimethylamine N-Oxide Prevents the Progression of Cardiac and Renal Dysfunction in a Rat Model of Chronic Cardiorenal Syndrome [J]. Front Pharmacol，2021，12：751380.
[6] Liu J，Lai L，Lin J，et al. Ranitidine and finasteride inhibit the synthesis and release of trimethylamine N-oxide and mitigates its cardiovascular and renal damage through modulating gut microbiota [J]. Int J Biol Sci，2020，16（5）：790- 802.
[7] Xu KY，Xia GH，Lu JQ，et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients [J]. Sci Rep，2017，7（1）：1445.
[8] Pelletier CC，Croyal M，Ene L，et al. Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease： Contribution of Decreased Glomerular Filtration Rate [J]. Toxins （Basel），2019，11（11）：635.
[9] Johnson C，Prokopienko AJ，West RE，et al. Decreased Kidney Function Is Associated with Enhanced Hepatic Flavin Monooxygenase Activity and Increased Circulating Trimethylamine N-Oxide Concentrations in Mice [J]. Drug Metab Dispos，2018，46（9）：1304-1309.
[10] 袁婷婷，谢圣芳.肠源性代谢产物氧化三甲胺与心肾疾病的相关研究进展[J].解放军医学院学报，2021，42（9）：978-982.
[11] Fryc J，Naumnik B. Thrombolome and Its Emerging Role in Chronic Kidney Diseases [J]. Toxins （Basel），2021，13（3）：223.
[12] Ke Y，Li D，Zhao M，et al. Gut flora-dependent metabolite Trimethylamine-N-oxide accelerates endothelial cell senescence and vascular aging through oxidative stress [J]. Free Radic Biol Med，2018，116：88-100.
[13] Zhang W，Miikeda A，Zuckerman J，et al. Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice [J]. Sci Rep，2021，11（1）：518.
[14] Sun G，Yin Z，Liu N，et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity [J]. Biochem Biophys Res Commun，2017，493（2）：964-970.
[15] Gupta N，Buffa JA，Roberts AB，et al. Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease [J]. Arterioscler Thromb Vasc Biol，2020，40（5）：1239-1255.
[16] Tang W，Li DY，Hazen SL. Dietary metabolism，the gut microbiome，and heart failure [J]. Nat Rev Cardiol，2019，16（3）：137-154.
[17] Zheng Y，Tang Z，You L，et al. Trimethylamine-N-oxide is an independent risk factor for hospitalization events in patients receiving maintenance hemodialysis [J]. Ren Fail，2020， 42（1）：580-586.
[18] Stubbs JR，Stedman MR，Liu S，et al. Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with ESKD Receiving Maintenance Hemodialysis [J]. Clin J Am Soc Nephrol，2019，14（2）：261-267.
[19] Fu D，Shen J，Li W，et al. Elevated Serum Trimethylamine N-Oxide Levels Are Associated with Mortality in Male Patients on Peritoneal Dialysis [J]. Blood Purif，2021，50（6）：837-847.
[20] Zhao Y，Wang W，Dong Z. Trimethylamine N-Oxide and mortality in hemodialysis patients：like a mystery [J]. Ren Fail，2021，43（1）：463-464.
[21] Ravid JD，Kamel MH，Chitalia VC. Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease [J]. Nat Rev Nephrol，2021，17（6）：402-416.
[22] Kyriakidis NC，Cobo G，Dai L，et al. Role of Uremic Toxins in Early Vascular Ageing and Calcification [J]. Toxins （Basel），2021，13（1）：26.
[23] Hou K，Wu ZX，Chen XY，et al. Microbiota in health and diseases [J]. Signal Transduct Target Ther，2022，7（1）：135.
[24] Rysz J，Franczyk B，?覵awiński J，et al. The Impact of CKD on Uremic Toxins and Gut Microbiota [J]. Toxins （Basel），2021，13（4）：252.
[25] Zhang P，Zou JZ，Chen J，et al. Association of trimethylamine N-Oxide with cardiovascular and all-cause mortality in hemodialysis patients [J]. Ren Fail，2020，42（1）：1004- 1014.
[26] Naghipour S，Cox AJ，Peart JN，et al. Trimethylamine N-oxide： heart of the microbiota-CVD nexus? [J]. Nutr Res Rev，2021，34（1）：125-146.
[27] Zeng Y，Guo M，Fang X，et al. Gut Microbiota-Derived Trimethylamine N-Oxide and Kidney Function： A Systematic Review and Meta-Analysis [J]. Adv Nutr，2021，12（4）：1286-1304.
[28] Croci S，D’Apolito LI，Gasperi V，et al. Dietary Strategies for Management of Metabolic Syndrome：Role of Gut Microbiota Metabolites [J]. Nutrients，2021，13（5）：1389.
[29] 朱昭章，周凡力，卢岚.中青年维持血液透析患者氧化三甲胺与轻度认知功能损害相关性临床研究[J].临床荟萃，2019，34（11）：991-994.
[30] Chang D，Xu X，Yang Z，et al. Trimethylamine-N-oxide （TMAO） and clinical outcomes in patients with end-stage kidney disease receiving peritoneal dialysis [J]. Perit Dial Int，2021：8968608211051809.
[31] Farhangi MA，Vajdi M，Asghari-Jafarabadi M. Gut microbiota-associated metabolite trimethylamine N-Oxide and the risk of stroke：a systematic review and dose-response meta-analysis [J]. Nutr J，2020，19（1）：76.
[32] Carrero JJ，González-Ortiz A，Avesani CM，et al. Plant-based diets to manage the risks and complications of chronic kidney disease [J]. Nat Rev Nephrol，2020，16（9）：525-542.
[33] Fu BC，Hullar M，Randolph TW，et al. Associations of plasma trimethylamine N-oxide，choline，carnitine，and betaine with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study [J]. Am J Clin Nutr，2020，111（6）：1226-1234.
[34] Li C，Liang Y，Qiao Y. Messengers From the Gut：Gut Microbiota-Derived Metabolites on Host Regulation [J]. Front Microbiol，2022，13：863407.
京公网安备 11010502046598号